// App-Quantinova.ai

1068 : Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer.

Researchers

Presenter

  • Peng Yuan

Principal Investigators

  • Feng Du

  • Jiayu Wang

  • Fei Ma

  • Ying Fan

  • Binghe Xu

Medical Centers

  • Chinese Academy of Medical Sciences, Beijing, China

  • Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Cancer Institute/Hospital Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC), Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

  • Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Carboplatin

  • Epirubicin

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01150513

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved